117 related articles for article (PubMed ID: 36053771)
1. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R
J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771
[TBL] [Abstract][Full Text] [Related]
2. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA
Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013
[TBL] [Abstract][Full Text] [Related]
3. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
[TBL] [Abstract][Full Text] [Related]
4. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K
J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674
[TBL] [Abstract][Full Text] [Related]
5. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Yu HA; Goto Y; Hayashi H; Felip E; Chih-Hsin Yang J; Reck M; Yoh K; Lee SH; Paz-Ares L; Besse B; Bironzo P; Kim DW; Johnson ML; Wu YL; John T; Kao S; Kozuki T; Massarelli E; Patel J; Smit E; Reckamp KL; Dong Q; Shrestha P; Fan PD; Patel P; Sporchia A; Sternberg DW; Sellami D; Jänne PA
J Clin Oncol; 2023 Dec; 41(35):5363-5375. PubMed ID: 37689979
[TBL] [Abstract][Full Text] [Related]
6. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced
Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA
Future Oncol; 2024 May; 20(15):969-980. PubMed ID: 38095056
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
Takahashi S; Karayama M; Takahashi M; Watanabe J; Minami H; Yamamoto N; Kinoshita I; Lin CC; Im YH; Achiwa I; Kamiyama E; Okuda Y; Lee C; Bang YJ
Clin Cancer Res; 2021 Nov; 27(21):5771-5780. PubMed ID: 34426442
[TBL] [Abstract][Full Text] [Related]
8. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
[TBL] [Abstract][Full Text] [Related]
9. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im SA; Nowecki Z; Sohn J; Laurentiis M; Jañez NM; Adamo B; Lee KS; Jung KH; Rubovszky G; Tseng LM; Lu YS; Yuan Y; Maxwell MJ; Haddad V; Khan SS; Rugo HS; Pistilli B
Future Oncol; 2024 Mar; 20(8):423-436. PubMed ID: 37387213
[TBL] [Abstract][Full Text] [Related]
10. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
[TBL] [Abstract][Full Text] [Related]
11. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
Shitara K; Yamaguchi K; Muro K; Yasui H; Sakai D; Oshima T; Fujimura M; Sato Y; Yamazaki S; Wakabayashi T; Sugihara M; Kamio T; Shoji H
Int J Clin Oncol; 2024 Jan; 29(1):27-35. PubMed ID: 37964066
[TBL] [Abstract][Full Text] [Related]
13. Raludotatug Deruxtecan, a CDH6-Targeting Antibody-Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models.
Suzuki H; Nagase S; Saito C; Takatsuka A; Nagata M; Honda K; Kaneda Y; Nishiya Y; Honda T; Ishizaka T; Nakamura K; Nakada T; Abe Y; Agatsuma T
Mol Cancer Ther; 2024 Mar; 23(3):257-271. PubMed ID: 38205802
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Hingorani P; Zhang W; Zhang Z; Xu Z; Wang WL; Roth ME; Wang Y; Gill JB; Harrison DJ; Teicher BA; Erickson SW; Gatto G; Kolb EA; Smith MA; Kurmasheva RT; Houghton PJ; Gorlick R
Mol Cancer Ther; 2022 Aug; 21(8):1318-1325. PubMed ID: 35657346
[TBL] [Abstract][Full Text] [Related]
15. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
[TBL] [Abstract][Full Text] [Related]
16. Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations.
Rolfo C; Del Re M; Russo A
Clin Cancer Res; 2023 Nov; 29(21):4317-4319. PubMed ID: 37656059
[TBL] [Abstract][Full Text] [Related]
17. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers.
DiPeri TP; Evans KW; Raso MG; Zhao M; Rizvi YQ; Zheng X; Wang B; Kirby BP; Kong K; Kahle M; Yap TA; Dumbrava EE; Ajani JA; Fu S; Keyomarsi K; Meric-Bernstam F
Clin Cancer Res; 2023 Nov; 29(21):4385-4398. PubMed ID: 37279095
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure-Response Analysis.
Yoshihara K; Kobayashi Y; Endo S; Fukae M; Hennig S; Kastrissios H; Kamiyama E; Garimella T; Abutarif M
J Clin Pharmacol; 2023 Nov; 63(11):1232-1243. PubMed ID: 37393579
[TBL] [Abstract][Full Text] [Related]
19. HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors.
Yonesaka K
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801379
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab Deruxtecan in Patients With
Goto K; Goto Y; Kubo T; Ninomiya K; Kim SW; Planchard D; Ahn MJ; Smit EF; de Langen AJ; Pérol M; Pons-Tostivint E; Novello S; Hayashi H; Shimizu J; Kim DW; Kuo CH; Yang JC; Pereira K; Cheng FC; Taguchi A; Cheng Y; Feng W; Tsuchihashi Z; Jänne PA
J Clin Oncol; 2023 Nov; 41(31):4852-4863. PubMed ID: 37694347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
